Moderna Claims Their Coronavirus Vaccine Is 94.5% Effective, According To New Data

The Moderna vaccine is 94.5% effective against fighting Covid-19, making it the second vaccine with an over 90% effectiveness rate.

Embed from Getty Images

Moderna released data to the general public early Monday morning claiming that their Covid-19 vaccine, which has been in the works since the spring, is testing as being 94.5% effective against the coronavirus. This extremely high percentage has scientists excited, especially considering this is now the second vaccine option that is proving to be highly successful in killing this virus and curbing the spread. 

“These are obviously very exciting results. It’s just as good as it gets — 94.5% is truly outstanding,” said Dr. Anthony Fauci, the nation’s top infectious disease doctor, to the press on Monday morning. Members of Moderna’s Data Safety and Monitoring Board – which is an independent panel hired to analyze Moderna’s clinical data through a second lens – confirmed these results on Sunday afternoon. 

Fauci claims that vaccinations could begin as soon as the end of December, starting with higher risk groups like healthcare providers and other essential workers, and then moving to more general populations in the spring; beginning with parts of the country that are seeing the highest spikes in cases as the weeks progress. Dr. Tal Zacks is Moderna’s chief medical officer who recently spoke with the media about this amazing accomplishment. 

“It was one of the greatest moments in my life and my career, to be able to develop this vaccine and see the ability to prevent symptomatic disease with such high efficacy.”

As most of us know last week Pfizer announced that their early clinical data showed its vaccine as also testing at more than 90% effective against Covid-19. As time goes on, more vaccines will likely prove to be just as effective as well which is amazing news for a world with a population of nearly 8 billion individuals who will need to be vaccinated. 

In Moderna’s trial specifically, 15,000 participants were given a shot of saline as a placebo vaccine that would have no effect on the body. Over several months 90 of those individuals developed Covid-19 with 11 developing severe forms of the disease. Another 15,000 individuals were given the actual vaccine, and only five of them developed Covid-19 but none of the cases were severe. The company also claims that the vaccine did not show any serious side effects either besides a small percentage of individuals experiencing body or headaches.

Moderna is set to apply their vaccine to the US Food and Drug Administration for authorization as soon as the company compiles all the safety data and delivers it to the FDA later this month; something Pfizer will also be doing this month. As mentioned, Fauci believes high priority groups like healthcare workers, the elderly, and people with severe underlying health conditions, will be vaccinated first.

Embed from Getty Images

“I think that everybody else will start to get vaccinated towards the end of April, and that will go into May, June, July. It will take a couple of months to do.”g, but the victim.”

Embed from Getty Images

Pfizer and Moderna both used the same technique in creating their vaccine against Covid-19, so it makes sense that the two are showing such astounding results so close to one another. Basically, both of the vaccines deliver messenger RNA to your body’s immune systems. Messenger RNA, or mRNA, is a genetic “recipe” that tells your immune system how to make the little spikes that sit around the coronavirus itself. If an individual who’s been vaccinated is later exposed to Covid-19, the antibodies in your body that were created with that “recipe” will begin to attack the virus. 

“There has always been skepticism about mRNA — it’s brand new and would it work? What we saw in the trials is there was no real safety concern, and the efficacy is quite impressive. We saw nearly identical results with Pfizer and Moderna, and it almost really validates the mRNA platform,” Fauci said. Research on mRNA vaccines is nothing new, however, actual vaccines on the market using this technique are rare. 

Fauci’s agency, the National Institute of Allergy and Infectious Diseases, has collaborated with Moderna on the development of its vaccine based on the previous data that the institute had acquired regarding mRNA vaccines. In both Pfizer and Moderna’s case, their vaccines would be given in two doses several weeks apart. 

The main difference between the Pfizer and Moderna vaccine is Pfizer’s needs to be kept at minus 75 degrees Celsius; for context no other vaccine available in the US right now needs to be kept that cold. Moderna’s vaccine only needs to be kept at minus 20 degrees Celsius, which is the same temperature the chickenpox vaccine must be kept at. This is an issue because the average pharmacy and doctor’s office doesn’t have a freezer that gets that cold. Regardless, both vaccines should be seeking approval by the end of the month, so only time will tell when they’ll really be available.